'UniQure restructuring but strong cash position'

 Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~

~ Initiated patient screening for three additional Phase I/II studies in mesial temporal lobe epilepsy, SOD1 ALS, and Fabry disease ~

~ Today, announced an organizational restructuring intended to streamline operations; Together with the recent sale of the Lexington manufacturing facility, these changes are expected to reduce headcount by 65% and lower recurring cash burn by $75 million per year including savings from the retirement of $50 million of debt ~

~ Strong cash position of approximately $524 million as of June 30, 2024, expected to fund operations through the end of 2027 and multiple value-generating inflection points ~

https://www.globenewswire.com/news-release/2024/08/01/2922648/0/en/uniQure-Announces-Second-Quarter-2024-Financial-Results-and-Provides-Company-Update.html